Document Report Card
Basic Information
ID: ALA4396891
Journal: Eur J Med Chem
Title: Recent update on anti-dengue drug discovery.
Authors: Dighe SN, Ekwudu O, Dua K, Chellappan DK, Katavic PL, Collet TA.
Abstract: Dengue is the most important arthropod-borne viral disease of humans, with more than half of the global population living in at-risk areas. Despite the negative impact on public health, there are no antiviral therapies available, and the only licensed vaccine, Dengvaxia®, has been contraindicated in children below nine years of age. In an effort to combat dengue, several small molecules have entered into human clinical trials. Here, we review anti-DENV molecules and their drug targets that have been published within the past five years (2014-2018). Further, we discuss their probable mechanisms of action and describe a role for classes of clinically approved drugs and also an unclassified class of anti-DENV agents. This review aims to enhance our understanding of novel agents and their cognate targets in furthering innovations in the use of small molecules for dengue drug therapies.
CiteXplore: 31128447